ArchiveJanuary 2018

Future Directions for Laboratory Animal Law in the US

Animals in Research is an Integral part of MS research. Like or Loathe it, it is occurring, but times are changing. Do you want to listen to a Day Webinar? Future Directions for Laboratory Animal Law in the United States In the United States, two major federal laws apply to vertebrate animals used in laboratory research.  The first of these two statutes, the Animal Welfare Act (AWA, under...

Making T reg cells. Explaining the daclizumab conundrum

How does daclicumab work? Are immunologists fudging the mechanisms to keep dogma alive? T regulatory cells that express CD25 and Fox3P are the main way that immunologists think that autoimmunity is blocked. However, a dirty little fact causes problems:-( as blockade of CD25 to inhibit cell function with daclizumab does not make MS worse, it makes it better.  But it should make things worse...

Is it right to go off-label? the rituximab story continues to run….

CD20 depletion seems an obvious choice when you look at the real-life data. The Swedish neurologists are walking-the-talk. It looks as if the majority of people with MS are being treated with rituximab off-label? How come? I was under the impression that this was illegal under EU law. EU law is meant to protect Pharma’s interests, i.e. healthcare systems are meant to support licensed drugs...

Newsflash: the wait is over ocrelizumab finally gets its EU marketing authorisation

If you have PPMS, and live in Europe, you are one step closer to having a disease-modifying therapy for your MS. If you have PPMS and live in England you have to wait for NICE to determine whether or not ocrelizumab is a cost-effective treatment to slow down your disease progression.  To help manage expectations I anticipate NICE saying no for the PPMS indication. Ocrelizumab will be priced...

Guest post: FAIR data for next generation management of MS

Transforming the population based management of today into an individualized, personalized and precision level management is a major goal in research. I believe, the key to reach this next level is FAIR data. Every day, young people are diagnosed with MS. People with MS struggle with a lot of insecurities about the future. For example, they were planning to buy a car, but will they be able to use...

Guest post: Familial MS: do your genes seal your fate?

MS is not considered a hereditary disorder, as there is no specific gene transmitted from parent to child that causes the disease (not yet confirmed! We’ve covered the topic on the blog before). However, around 20% of people with MS report another family member with the condition and the risk differs depending on the degree of relatedness. These pwMS have what we call “familial MS” (FMS)...

Anti-depressant for Progressive MS: can mice go to man?

Can we modify the course of progressive MS with anti-depressants?  Faissner S, Mishra M, Kaushik DK, Wang J, Fan Y, Silva C, Rauw G, Metz L, Koch M, Yong VW. Systematic screening of generic drugs for progressive multiple sclerosis identifies clomipramine as a promising therapeutic. Nat Commun. 2017 Dec 19;8(1):1990. doi: 10.1038/s41467-017-02119-6. The treatment of progressive MS...

Predicting low lymphocyte counts after DMTs

How important is it to predict lymphopenia in pwMS starting DMTs?  Mult Scler Relat Disord. 2017 Dec 14;20:51-57. doi: 10.1016/j.msard.2017.12.003. [Epub ahead of print] Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count. Baharnoori M, Gonzalez CT, Chua A, Diaz...

HSCT on the Increase

How common is HSCT being performed as a treatment for MS and which countries are using it most?  You may be surprised by the results.  Snowden JA, Badoglio M, Labopin M, Giebel S, McGrath E, Marjanovic Z, Burman J, Moore J, Rovira M, Wulffraat NM, Kazmi M, Greco R, Snarski E, Kozak T, Kirgizov K, Alexander T, Bader P, Saccardi R, Farge D. Evolution, trends, outcomes, and...

Regional Specific Astrocyte Function for Repair and how cholesterol may link to Repair

EAE gets explained in many ways and you asked about a report on how researchers find a way to repair nerves.  Is this the right view, because we are about to do a trial that will do the exact opposite? Well not Quite the opposite. Is the cholesterol pathway opening the door to repair Itoh N, Itoh Y, Tassoni A, Ren E, Kaito M, Ohno A, Ao Y, Farkhondeh V, Johnsonbaugh H, Burda J, Sofroniew MV...

Translate

Categories

Recent Posts

Recent Comments

Archives